EN | RU
EN | RU

Help Support

Back

Abrocitinib therapy improves symptoms and quality of life in people with atopic dermatitis

Abrocitinib therapy improves symptoms and quality of life in people with atopic dermatitis Abrocitinib therapy improves symptoms and quality of life in people with atopic dermatitis
Abrocitinib therapy improves symptoms and quality of life in people with atopic dermatitis Abrocitinib therapy improves symptoms and quality of life in people with atopic dermatitis

What's new?

Abrocitinib oral therapy can be used to alleviate symptoms and enhance the quality of life in atopic dermatitis patients.

The routine use of once-daily, oral abrocitinib (Janus kinase 1 selective inhibitor)  dosed at 100 or 200 mg can be effective in improving the symptoms and health-related quality of life (QoL) in adolescent and adults suffering from moderate-to-severe atopic dermatitis (AD) as deciphered from a pooled analysis of 3 studies issued in American Journal of Clinical Dermatology.

Jonathan I. Silverberg et al. studied the effect of abrocitinib in AD patients in terms of patient-reported outcomes of specific signs and symptoms linked with the disease and QoL. The pooled data from one phase IIb and two phase III trials comprising of 942 individuals with atopic dermatitis were examined.

Itch (Night Time Itch Scale (NTIS)), overall severity, and multiple scales concerning the signs and symptoms were reported under the assessments of patient-reported outcomes. Anxiety, depression (Hospital Anxiety and Depression Scales (HADS)), fatigue, disease- and general health-linked QoL, and work and general efficiency among working patients via Work Productivity and Activity Impairment Questionnaire: Atopic Dermatitis (WPAI: AD) were also evaluated.

As found, there were improvements across all the patient-reported outcomes from week 2 to week 12 in patients in 200 mg, 100 mg, and placebo as shown in the following table 1:


The results of this analysis offered notable information on the efficacy of abrocitinib from the perception of patients and complement clinician-reported efficacy and safety outcomes, as concluded.

Source:

American Journal of Clinical Dermatology

Article:

Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes

Authors:

Jonathan I. Silverberg et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: